How to Qualify for Medicare's GLP-1 Bridge in 2026: $50/Month Wegovy, Zepbound, and Foundayo Starting July 1

For years, Medicare flatly refused to pay for weight-loss medication. If your doctor prescribed Wegovy purely to help you lose weight, you were on your own — and "on your own" meant roughly $1,000 a month at the pharmacy counter. That changes on July 1, 2026, when Medicare launches the GLP-1 Bridge, a temporary demonstration that opens the door to Wegovy, Zepbound, and Foundayo for a flat $50 copay per month.

The Bridge is a big deal, but it isn't open to everyone with a Medicare card. There are clinical thresholds, a prior authorization step, a list of which formulations count, and a 2027 transition that can quietly cut off your coverage if you don't plan ahead. This guide walks through who qualifies, exactly what to bring to your doctor's appointment, what the $50 copay does and doesn't count toward, and how to avoid the most common ways people get tripped up.

The GLP-1 Bridge is a short-term federal demonstration run by the Centers for Medicare & Medicaid Services. It exists for one reason: the permanent program — the BALANCE Model, short for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth — doesn't begin until January 2027, and Medicare didn't want eligible beneficiaries to wait another six months. The Bridge runs from July 1, 2026 through December 31, 2027, after which BALANCE becomes the primary path to GLP-1 coverage on Medicare.

If you're enrolled in a standalone Part D prescription drug plan (PDP) or a Medicare Advantage plan that includes drug coverage (MA-PD) and you meet the clinical criteria, your provider can submit a prior authorization request through the Bridge. Once approved, your pharmacy collects a flat $50 per 30-day supply — no coinsurance, no deductible to meet first, no progressive cost-sharing tiers.

Eligibility for the Bridge has two parts: a coverage check and a clinical check. You need to pass both.

1. The Coverage Check

You must be enrolled in one of the following for plan year 2026:

• A standalone Medicare Part D prescription drug plan (PDP)
• A Medicare Advantage plan with drug coverage (MA-PD)
• A Special Needs Plan (SNP)
• An employer or union group waiver plan (EGWP)
• The Limited Income Newly Eligible Transition (LI NET) program

If you have Original Medicare without a Part D plan, the Bridge won't help you — you'd need to add a Part D plan during a valid enrollment window first. If you're on Medicaid (without Medicare), the BALANCE Model may eventually cover you starting in 2027 under separate state rules, but the Bridge itself is Medicare-only.

2. The Clinical Check

Your provider needs to confirm you meet the BMI and health-condition criteria. The general thresholds are:

• BMI of 35 or higher on its own, or
• BMI of 27 or higher with a qualifying medical condition, such as hypertension, heart failure, chronic kidney disease, pre-diabetes, established cardiovascular disease, or a history of cardiovascular events

These are baseline criteria — your specific Part D plan may layer additional documentation requirements on top, like a recent A1C test for the pre-diabetes pathway or a cardiologist's notes for the cardiovascular path. Bring as much of your record as you can to the appointment.

Not every GLP-1 medication is included. As of the Bridge launch, the covered drugs are:

If your doctor prescribes Zepbound's single-dose pen instead of the KwikPen, the Bridge will reject the prior authorization. Make sure the prescription specifies the KwikPen formulation if Zepbound is your medication of choice.

Every Bridge prescription starts with a prior authorization (PA) request from your prescriber. Here's how the process actually moves:

1. Book an appointment with your prescriber. Bring your most recent BMI, blood pressure readings, A1C if you have one, and any cardiology notes. The more documentation you arrive with, the smoother the PA review.
2. Your provider submits the PA request to your Part D plan, along with a prescription specifying an eligible drug and formulation.
3. Your plan responds within 7 calendar days for a standard request or 72 hours for an expedited (urgent) request. These are mandatory 2026 turnaround times under separate CMS prior authorization rules — your plan doesn't get to take longer than that.
4. If approved, your plan files a notation in their system, and the next time you fill the prescription, the pharmacy collects only $50.
5. If denied, your plan must give you a specific reason. Common ones: incomplete BMI documentation, no qualifying condition on file, or the wrong drug formulation. Appeals are usually decided within another 7 days.

Without coverage, GLP-1 medications run about $900 to $1,300 per month at retail. Even with manufacturer coupons, brand-name versions used purely for weight loss have historically been out of reach for most people on Medicare, because manufacturer copay cards generally exclude Medicare and Medicaid enrollees.

At a $50 flat copay, the Bridge represents roughly a 95% reduction in monthly out-of-pocket cost for eligible beneficiaries. Over a full year, that's a difference of about $10,000 to $15,000 in pharmacy spending — for many Medicare households, this is by far the largest single change in the 2026 prescription benefit.

One nuance to plan around: because the Bridge $50 doesn't count toward your Part D out-of-pocket cap, your other prescription costs continue accumulating toward the $2,100 ceiling normally. So if you have additional expensive medications, your standard Part D coverage still works the same way underneath — the Bridge sits alongside it rather than replacing it.

This is the part most articles bury, and it's the part that will trip up the most people. The Bridge ends December 31, 2027. Starting January 1, 2027, the permanent BALANCE Model is the new pathway — but BALANCE is voluntary for Part D plans. Not every plan signs up.

If you start on the Bridge in mid-2026, your coverage does not automatically continue on January 1, 2027. You need to confirm during the 2026 Medicare Open Enrollment Period (October 15 to December 7, 2026) that your current Part D or MA-PD plan has enrolled in BALANCE for 2027. If your plan opts out, you'll need to switch to a participating plan during that window — otherwise you'll lose your GLP-1 coverage when the Bridge ends and could end up paying retail again, mid-treatment.

If you have commercial health insurance through an employer or the Marketplace, the Bridge doesn't apply to you. Coverage of Wegovy, Zepbound, or Foundayo depends entirely on your plan's formulary, and most commercial formularies still exclude GLP-1s when used purely for weight loss. They may cover them when prescribed for type 2 diabetes (in which case Ozempic or Mounjaro is usually the on-label choice) or for established cardiovascular disease.

Before assuming you're out of luck on a commercial plan, check three things: the formulary itself, whether your plan offers a separate weight-management benefit, and whether the manufacturer's copay card brings the retail price into reach. Manufacturer cards typically aren't allowed for people on Medicare or Medicaid, but they often work on commercial plans.

Bring as much of this as you can to the visit where you ask about a GLP-1 prescription. A complete chart on day one usually means a smoother prior authorization on day three.

1. Current and recent BMI readings. The qualifying figure is your most recent BMI, but a trend over the last year helps the case.
2. Blood pressure log. If hypertension is your qualifying condition, your plan wants to see numbers, not just a diagnosis code.
3. Most recent A1C and fasting glucose. Pre-diabetes is one of the qualifying conditions, and the numbers carry the request.
4. Any cardiology notes or imaging. If established cardiovascular disease is your pathway, the cardiologist's documentation is what your Part D plan reviews.
5. A list of medications you've tried. Many plans want to see that lifestyle interventions or other treatments have been attempted first.
6. Your Part D or MA-PD plan card. Your provider's office needs the plan ID to route the prior authorization correctly.

The GLP-1 Bridge is a genuinely meaningful change. For Medicare beneficiaries who meet the criteria, it cuts the cost of these medications by roughly 95% and finally treats obesity as the chronic condition the clinical evidence has long shown it to be. But it isn't automatic, it isn't permanent, and a step missed in October 2026 can mean a coverage gap in January 2027. Do the prior authorization, mark the open enrollment dates on your calendar, and you'll keep the savings in place all the way through to the permanent program in 2027 and beyond.